Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Account Payables (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Change in Account Payables for 12 consecutive years, with $419000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 48.34% year-over-year to $419000.0, compared with a TTM value of -$695000.0 through Sep 2025, down 90.93%, and an annual FY2024 reading of -$297000.0, up 79.17% over the prior year.
  • Change in Account Payables was $419000.0 for Q3 2025 at CytomX Therapeutics, up from -$49000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $3.3 million in Q3 2022 and bottomed at -$2.4 million in Q4 2022.
  • Average Change in Account Payables over 5 years is -$117263.2, with a median of -$261000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables plummeted 661.54% in 2021, then soared 1875.68% in 2022.
  • Year by year, Change in Account Payables stood at $1.2 million in 2021, then tumbled by 294.67% to -$2.4 million in 2022, then surged by 86.18% to -$328000.0 in 2023, then increased by 20.43% to -$261000.0 in 2024, then surged by 260.54% to $419000.0 in 2025.
  • Business Quant data shows Change in Account Payables for CTMX at $419000.0 in Q3 2025, -$49000.0 in Q2 2025, and -$804000.0 in Q1 2025.